WallStSmart

Intapp Inc (INTA)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intapp Inc generates 110% more annual revenue ($543.34M vs $258.90M). INTA leads profitability with a -4.4% profit margin vs -15.5%. INTA earns a higher WallStSmart Score of 42/100 (D).

INTA

Hold

42

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 8.3Quality: 4.3
Piotroski: 4/9Altman Z: 0.65

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INTAUndervalued (+41.1%)

Margin of Safety

+41.1%

Fair Value

$40.83

Current Price

$22.45

$18.38 discount

UndervaluedFair: $40.83Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INTA2 strengths · Avg: 9.0/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.7%8/10

15.7% revenue growth

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

INTA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.4%2/10

ROE of -5.4% — below average capital efficiency

Altman Z-ScoreHealth
0.652/10

Distress zone — elevated risk

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : INTA

The strongest argument for INTA centers on PEG Ratio, Revenue Growth. Revenue growth of 15.7% demonstrates continued momentum. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : INTA

The primary concerns for INTA are EPS Growth, Market Cap, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

INTA profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INTA scores higher overall (42/100 vs 41/100) and 15.7% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intapp Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Intapp, Inc., through its subsidiary, Integration Appliance, Inc., provides industry-specific cloud-based software solutions for the financial and professional services industry in the United States, the United Kingdom, and internationally. The company is headquartered in Palo Alto, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?